Description
Rechalange is not approved or commonly used in the treatment of colorectal cancer. There are no clinical trials or established indications for its use in this context.
Mechanism of Action
Rechalange is not a recognized medication for cancer treatment and there are no specific mechanisms of action documented in the literature related to colorectal cancer.
Side Effects
None documented for colorectal cancer treatment; not applicable
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07178717
Phase 2
Not yet recruiting
A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations
Spain